Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Seaport Therapeutics, Inc.

NASDAQ: SPTX · Life Sciences · 3 alerts · CIK 2042347

Share price
$19.12Close, Nov 16
Market cap
$1.02B
Shares outstanding
53.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Seaport Therapeutics, Inc. filings on SEC EDGAR ↗

7:09 AM ET 10-Q
Financial Results

Seaport Therapeutics Q3 2026 Results: Net Loss of $26.4M, Loss Widens

Seaport Therapeutics is a clinical-stage therapeutics company that recently transitioned to public markets, reporting 53,530,550 shares of voting common stock outstanding as of October 2026. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, focusing on advancing its clinical pipeline and research programs.

Key figure
Net loss $26.4M
7:04 AM ET 8-K
Financial Results

Seaport Therapeutics Financial Results

Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.

“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”

Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics

“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”

Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.